Seres Therapeutics Inc. ( (MCRB) ) has released its Q3 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Seres Therapeutics, Inc. is a clinical-stage company specializing in live biotherapeutics aimed at improving patient outcomes in medically vulnerable populations, with a focus on developing innovative treatments for infectious and immune diseases.
In its third quarter of 2025 financial report, Seres Therapeutics announced significant developments in its SER-155 program, alongside a notable improvement in financial performance compared to the previous year. The company is actively working on finalizing a Phase 2 study protocol for SER-155, targeting bloodstream infections in patients undergoing stem cell transplants.
Key financial highlights include a net income of $8.2 million from continuing operations, a significant turnaround from a $51 million loss in the same period last year. This improvement was largely driven by a $27.2 million gain from the sale of VOWST to Nestlé. The company also reported a decrease in both research and development expenses and general administrative costs, reflecting recent cost-reduction measures. Additionally, Seres received a $3.6 million grant from CARB-X to support the development of an oral liquid formulation of SER-155, potentially broadening patient access.
Seres Therapeutics is optimistic about the future, with plans to fund operations through the second quarter of 2026. The company is focused on advancing its SER-155 program and exploring new therapeutic opportunities, while continuing to seek strategic partnerships and funding to support its ambitious research and development goals.